CEDARS-SINAI MEDICAL CENTER

A small study published in the Journal of Assisted Reproduction and Genetics found that isotretinoin (Accutane) stimulated sperm production in 11 out of 30 men with severe male infertility.

Researchers discovered that CDK4/6 inhibitors create an immunosuppressive tumor microenvironment in some HR+/HER2- breast cancers, leading to treatment resistance through gamma delta T-cells and specific macrophage populations.

Percheron Therapeutics has licensed HMBD-002, a first-in-class monoclonal antibody targeting the VISTA immune checkpoint, from Hummingbird Bioscience in a deal worth up to $290 million.

Recent research shows increasing overtreatment of prostate cancer in older men with limited life expectancy, with radiation therapy use rising from 16% to 39% despite guidelines recommending against such interventions.

Gilead Sciences and Merck's phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrated statistically significant improvement in progression-free survival with Trodelvy plus Keytruda compared to Keytruda with chemotherapy in metastatic TNBC patients.

A clinical trial found that hospital-based addiction consultation services more than doubled the rate of medication initiation for opioid use disorder during hospitalization (57.3% vs 26.7% with usual care).

ABVC BioPharma has secured three global licensing agreements valued at $959 million across psychiatric disorders, ophthalmology, and oncology, expecting to generate approximately $19 million in cash revenue in 2025.

• The FDA has approved Itovebi in combination with Ibrance and Faslodex for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, based on the INAVO120 trial results. • Healthcare providers must carefully monitor blood sugar levels in patients receiving Itovebi, as the PIK3CA pathway affects glucose metabolism and can cause hyperglycemia. • Treatment success requires a coordinated approach involving oncologists, endocrinologists, nurses, and pharmacists, particularly for patients with pre-existing diabetes.

Recent data from six randomized controlled trials involving 1,887 patients demonstrates significant benefits of endovascular therapy (EVT) in large-core stroke patients, with functional independence rates of 19.5% versus 7.9% for medical management alone.

Recent FDA approvals of transcatheter tricuspid valve devices, including Evoque and TriClip, are transforming treatment options for tricuspid regurgitation patients who historically avoided surgery.